“Interim Safety Results of Amlitelimab (anti-OX40 ligand antibody) in Participants With Moderate-to-Severe Atopic Dermatitis From the RIVER-AD Phase 2/3 Ongoing Open-Label Study”, J of Skin, vol. 9, no. 6, p. s602, Nov. 2025, doi: 10.25251/mq5bgn88.